BioSpace News Archive

Alvotech, today, announced reaching the primary completion date in the switching study for AVT02, the company’s proposed interchangeable biosimilar to Humira®.

ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. announced the anticipated closing of their previously announced merger to be effective after the close of the market, June 15, 2021.

Advicenne, a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, provides an update on its activities following its Annual General Meeting, which was held virtually on June 14, 2021.

LifeLabs is pleased to announce its latest milestone in COVID-19 molecular diagnostic testing, completing over 2 million tests for Canadians and their health care providers

Sepha has achieved micro leak detection down to one micron (1µm) with the development of a new high performance leak tester for CCIT (Container Closure Integrity Testing) applications.

AffyImmune Therapeutics, Inc., announced today the addition of Dr. Jim Mulé to its Scientific Advisory Board to provide strategic guidance for its scientific programs.

Eton today announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Senti Biosciences, Inc., a leading gene circuit company, today announced that it has signed a lease agreement for a property in Alameda, California for the build-out of its wholly-owned cell therapy manufacturing facility.

Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Human Health Innovation Conference on Tuesday, June 22, 2021, at 2:00 pm Eastern time.

ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced that all resolutions at the ICON Extraordinary General Meeting of the Company held on June 15, 2021 were all duly passed by shareholders.